Evidence map›Paper›PMID 38932349›Full record

ArticleVaccines2024

Exploring the Potentiality of a Plant Platform for Monoclonal Antibody Production in Veterinary Medicine.

Bertrand Morel, Claude Favrot, Lucie Mirande, Clemens Grünwald-Gruber, Virginie Stordeur, Louis Philippe Vezina, Loïc Faye, Véronique Gomord

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bertrand MorelANGANY Innovation, 1 Voie de l'Innovation, 27100 Val de Reuil, France.
Claude FavrotDermatology Unit, Clinical for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, 8006 Zurich, Switzerland.
Lucie MirandeANGANY Innovation, 1 Voie de l'Innovation, 27100 Val de Reuil, France.
Clemens Grünwald-GruberBOKU Core Facility Mass Spectrometry, BOKU University, Muthgasse 18, A-1190 Vienna, Austria.
Virginie StordeurANGANY Innovation, 1 Voie de l'Innovation, 27100 Val de Reuil, France.
Louis Philippe VezinaANGANY Inc., Suite 200, 873 St-Jean, Québec, QC G1R 1R2, Canada.
Loïc FayeANGANY Innovation, 1 Voie de l'Innovation, 27100 Val de Reuil, France.
Véronique GomordANGANY Innovation, 1 Voie de l'Innovation, 27100 Val de Reuil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Canine atopic dermatitis (CAD) is an allergic, inflammatory, and pruritic skin disease associated with the production of IgE antibodies against environmental allergens and mainly house dust mite allergens. This complex dermatological pathology involves Interleukin 31 (IL-31) as a central itch mediator. One of the most effective CAD treatments is a caninized monoclonal antibody (mAb) called Lokivetmab. It is produced in CHO cells and targets specifically canine IL-31 (cIL-31) and blocks its cellular messaging. This treatment has undoubtedly contributed to a breakthrough in dermatitis-related pruritus. However, its production in mammalian cells requires time-consuming procedures, high production costs, and investment. Plants are considered an emerging protein production platform for recombinant biopharmaceuticals due to their cost-effectiveness and rapidity for production. Here, we use transient expression in

Indexed as

cytokinesIL-31 inhibitionmonoclonal antibody (mAb)plant-made antibodyplant-made pharmaceuticalpruritus atopic dermatitis

Identifiers

PMID38932349
PMCPMC11209382

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.